Cargando…

An ultra-sensitive method to detect mutations in human RAS templates

The RAS family of small GTPases is mutated in roughly a fifth of human cancers. Hotspot point mutations at codons G(12), G(13), and Q(61) account for 95% of all these mutations, which are well established to render the encoded proteins oncogenic. In humans, this family comprises three genes: HRAS, N...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Siqi, Counter, Christopher M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584555/
https://www.ncbi.nlm.nih.gov/pubmed/35658790
http://dx.doi.org/10.1080/21541248.2022.2083895
_version_ 1784813293878116352
author Li, Siqi
Counter, Christopher M.
author_facet Li, Siqi
Counter, Christopher M.
author_sort Li, Siqi
collection PubMed
description The RAS family of small GTPases is mutated in roughly a fifth of human cancers. Hotspot point mutations at codons G(12), G(13), and Q(61) account for 95% of all these mutations, which are well established to render the encoded proteins oncogenic. In humans, this family comprises three genes: HRAS, NRAS, and KRAS. Accumulating evidence argues that oncogenic RAS point mutations may be initiating, as they are often truncal in human tumours and capable of inducing tumorigenesis in mice. As such, there is great interest in detecting oncogenic mutation in the RAS genes to understand the origins of cancer, as well as for early detection purposes. To this end, we previously adapted the microbial ultra-sensitive Maximum Depth Sequencing (MDS) assay for the murine Kras gene, which was capable of detecting oncogenic mutations in the tissues of mice days after carcinogen exposure, essentially capturing the very first step in tumour initiation. Given this, we report here the adaption and details of this assay to detect mutations in a human KRAS sequence at an analytic sensitivity of one mutation in a million independently barcoded templates. This humanized version of MDS can thus be exploited to detect oncogenic mutations in KRAS at an incredible sensitivity and modified for the same purpose for the other RAS genes.
format Online
Article
Text
id pubmed-9584555
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-95845552022-10-21 An ultra-sensitive method to detect mutations in human RAS templates Li, Siqi Counter, Christopher M. Small GTPases Brief Report The RAS family of small GTPases is mutated in roughly a fifth of human cancers. Hotspot point mutations at codons G(12), G(13), and Q(61) account for 95% of all these mutations, which are well established to render the encoded proteins oncogenic. In humans, this family comprises three genes: HRAS, NRAS, and KRAS. Accumulating evidence argues that oncogenic RAS point mutations may be initiating, as they are often truncal in human tumours and capable of inducing tumorigenesis in mice. As such, there is great interest in detecting oncogenic mutation in the RAS genes to understand the origins of cancer, as well as for early detection purposes. To this end, we previously adapted the microbial ultra-sensitive Maximum Depth Sequencing (MDS) assay for the murine Kras gene, which was capable of detecting oncogenic mutations in the tissues of mice days after carcinogen exposure, essentially capturing the very first step in tumour initiation. Given this, we report here the adaption and details of this assay to detect mutations in a human KRAS sequence at an analytic sensitivity of one mutation in a million independently barcoded templates. This humanized version of MDS can thus be exploited to detect oncogenic mutations in KRAS at an incredible sensitivity and modified for the same purpose for the other RAS genes. Taylor & Francis 2022-06-29 /pmc/articles/PMC9584555/ /pubmed/35658790 http://dx.doi.org/10.1080/21541248.2022.2083895 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Brief Report
Li, Siqi
Counter, Christopher M.
An ultra-sensitive method to detect mutations in human RAS templates
title An ultra-sensitive method to detect mutations in human RAS templates
title_full An ultra-sensitive method to detect mutations in human RAS templates
title_fullStr An ultra-sensitive method to detect mutations in human RAS templates
title_full_unstemmed An ultra-sensitive method to detect mutations in human RAS templates
title_short An ultra-sensitive method to detect mutations in human RAS templates
title_sort ultra-sensitive method to detect mutations in human ras templates
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584555/
https://www.ncbi.nlm.nih.gov/pubmed/35658790
http://dx.doi.org/10.1080/21541248.2022.2083895
work_keys_str_mv AT lisiqi anultrasensitivemethodtodetectmutationsinhumanrastemplates
AT counterchristopherm anultrasensitivemethodtodetectmutationsinhumanrastemplates
AT lisiqi ultrasensitivemethodtodetectmutationsinhumanrastemplates
AT counterchristopherm ultrasensitivemethodtodetectmutationsinhumanrastemplates